Candida Immune Complex

Test Code

95856

CPT Codes
86332<br /> **This test is not available for New York patient testing**

Preferred Specimen

2 mL frozen serum

Minimum Volume

1 mL

Instructions

Red-top tube with no additives or serum gel tube. Allow blood to clot for 30 minutes. Centrifuge at 3000 rpm for 10 minutes. Separate serum and freeze immediately. Ship frozen on dry ice. Submit in plastic screw-cap vial.

Transport Container

Plastic screw-cap vial

Transport Temperature

Frozen

Specimen Stability

Room temperature: Unacceptable
Refrigerated: 7 days
Frozen: 10 weeks

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Hemolyzed specimens • Specimens received at ambient temperature • Specimens received at refrigerated temperature • Specimens outside of listed stability

Methodology
Enzyme Linked Immunosorbent Assay (ELISA)

FDA Status
The performance characteristics of the listed assay was validated by BioAgilytix Diagnostics. The US FDA has not approved or cleared this test. The results of this assay can be used for clinical diagnosis without FDA approval. BioAgilytix Diagnostics is a CLIA certified, CAP accredited laboratory for performing high complexity assays such as this one.

Setup Schedule

Set up: Varies; Report available: 7 business days

Reference Range

<0.90 Index

Clinical Significance

Candida Immune Complexes which form in vivo are comprised of Candida Albicans antigen, anti-Candida IgG antibodies, and complement. The presence of these complexes is an indication of overgrowth of C. albicans in the gut. Candida overgrowth was first described by Brabander and associates in 1957. Diagnosis of the condition has been difficult due to the ubiquitous nature of Candida resulting in the existence of antibodies to it in a large percentage of the normal population. It is also difficult to isolate by culture from stool due to the overgrowth by normal intestinal flora. Symptoms of Candida intestinal overgrowth include bloating, itching, and skin rashes. Lehman and Reiss suggested that the presence of immune complexes to Candida is an objective means of diagnosing the condition. The results of Broughton and Lanson concluded that the marker for Candida immune complexes not only aid in diagnosing intestinal overgrowth, but that levels of complexes decrease during successful treatment.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.